Nuformix hosting online Q&A session on 13 June 2023

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company’s Executive Director, Dr Dan Gooding, will be hosting an online Q&A session at 5.30 p.m. GMT on Tuesday 13 June 2023. This session is open to all existing and prospective shareholders. Those who wish to attend should register via the following link where they will be provided with access details:

https://us02web.zoom.us/webinar/register/WN_fV_2UztcQLSl1S1tC4vTGg

Participants will have the opportunity to submit questions during the session, but questions are welcomed in advance and may be submitted to: [email protected]

Share on:

Written by: Amilia Stone

Find more news, interviews, share price & company profile here for:
Nuformix plc

Latest Company News

Dr Dan Gooding on Nuformix’s NXP002 opportunity in idiopathic pulmonary fibrosis

April 1, 2026

Executive Director Dr Dan Gooding discusses Nuformix’s NXP002 programme for idiopathic pulmonary fibrosis, the value of FDA orphan drug designation, and how the recent fundraise supports partnering discussions.

Nuformix Secures US Orphan Status for NXP002 as Licensing Talks Advance (video)

March 24, 2026

Nuformix strengthens its NXP002 programme with US orphan drug designation, unlocking market exclusivity in a region accounting for the majority of IPF revenues. With fresh capital and ongoing partner discussions, the company is positioning itself to advance a differentiated inhaled therapy while negotiating from strength.

Nuformix raises £1.0m through share placing to advance NXP002 programme

March 11, 2026

Nuformix plc has raised £1.0 million via a placing of 500 million new shares at 0.20p each. The proceeds will support additional pre-clinical studies and further development of its inhaled NXP002 treatment for pulmonary fibrosis.

Nuformix receives FDA Orphan Drug status for NXP002 IPF programme

March 10, 2026

The FDA has granted Orphan Drug Designation to tranilast lystate, the active compound in Nuformix’s NXP002 programme targeting idiopathic pulmonary fibrosis, a rare lung disease affecting fewer than 200,000 people in the United States.

Nuformix receives FDA clarification request and reports 408% oversubscription in Open Offer

November 12, 2025

Nuformix has received an FDA request for clarification on its Orphan Drug Designation application for tranilast under the NXP002 programme. The company also reported its Open Offer was oversubscribed by 408%, raising around £228,000 before expenses.